Fine-needle diathermy plus bevacizumab for corneal blood vessel growth

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this interventional trial, adults with corneal neovascularization receive both fine-needle diathermy to occlude abnormal vessels and a subconjunctival bevacizumab injection to curb VEGF-driven growth. Participants undergo baseline and follow-up ophthalmic assessments, including visual acuity, intraocular pressure, slit-lamp exam, corneal photography, and AS-OCT. The goal is to see if the combination can promote regression of neovessels while maintaining safety and tolerability. Eligibility requires stable CNV affecting at least one corneal quadrant, with several exclusion criteria to minimize risk. The study is led by HoChiMinh City Eye Hospital in Ho Chi Minh City, Vietnam, with assessments to monitor adverse events and efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age over 18 years.
* Diagnosis of corneal neovascularization involving at least one quadrant of the cornea, confirmed by slit-lamp examination.
* Corneal neovascularization is stable with no evidence of progression for at least 4 weeks.
* Agreement to participate in the study and ability to comply with outpatient follow-up requirements

Exclusion Criteria:

* Pregnant or breastfeeding women.
* History of hypersensitivity or allergy to bevacizumab or any component of the study medication.
* Presence of severe systemic disease that would preclude study participation or surgical intervention, including coagulation disorders or uncontrolled cardiovascular disease.
* Active ocular infection or acute conjunctivitis at the time of enrollment.
* Persistent corneal epithelial defect or delayed corneal epithelial healing.
* History of ocular surgery within 3 months before study enrollment.
* Corneal neovascularization associated with uncontrolled secondary glaucoma.
* Inability or unwillingness to comply with study treatment or follow-up visits.

Where it's running

• HoChiMinh City Eye Hospital
  Ho Chi Minh City, Xuan Hoa, Vietnam Recruiting

Study contacts

• Principal investigator: Minh Nhat Le, Master of Ophthalmology — HoChiMinh City Eye Hospital
• Study coordinator: Minh Nhat Le, Master of Ophthalmology
• Email: le.nminh93@gmail.com
• Phone: +84833399368

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Bevacizumab for severe HHT-related nosebleeds

  This study tests whether bevacizumab can help people with hereditary hemorrhagic telangiectasia who have severe nosebleeds.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07828015

• Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.

  Recruiting at 3 sites Phase 3 AstraZeneca · Anchorage, Alaska and 123 other locations · NCT07816666

• Trastuzumab plus bevacizumab vs bevacizumab alone as first-line maintenance therapy for ovarian cancer

  This trial tests whether adding trastuzumab to bevacizumab maintenance helps people with epithelial ovarian cancer after initial platinum-based therapy.

  Recruiting at 3 sites Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT07779538

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.